Mr. Marciniak will serve as a member of the senior management team and lead the company's enterprise-wide capital fundraising strategy, as well as its efforts to establish and maintain mutually beneficial relationships with key stakeholders to drive growth and position the company as a global leader in biopharmaceutical innovation.

These favorable outcomes deepen our commitment to advance this treatment through accelerated clinical trials, with the ultimate goal of making it available to patients globally.

PRINCETON, N.J. and SUZHOU, China, April 29, 2025 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced late-breaking presentation of preclinical study results of novel humanized FGFR2b antibody based ADC (TST105) at AACR Annual Meeting 2025. This ADC, with a novel topoisomerase I inhibitor payload by using glycosyltransferase mediated site-specific conjugation, demonstrated significantly enhanced anti-tumor activity compared to MMAE-based ADCs in preclinical gastric and colorectal tumor models.

PRINCETON, N.J. and SUZHOU, China, December 13, 2024 -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced late-breaking presentation of preclinical study results of novel humanized LIV-1 antibody based ADCs at 2024 San Antonio Breast Cancer Symposium (SABCS). The ADCs (ADC-1 and ADC-2) were engineered using Transcenta’s proprietary antibody with site-specifical conjugation of Topoisomerase I Inhibitor payloads and these ADCs demonstrated significantly higher tumor regression activities than MMAE based ADCs in triple-negative breast cancer (TNBC) tumor models.

Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66).

Phase II results reveal median PFS of 12.6 months in patients with CLDN18.2 high or medium expression, including in patients with PD-L1 CPS<5.